These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT mBio; 2021 Jan; 12(1):. PubMed ID: 33468703 [TBL] [Abstract][Full Text] [Related]
8. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539 [TBL] [Abstract][Full Text] [Related]
9. Potential inhibitors of SARS-CoV-2: recent advances. Jamalipour Soufi G; Iravani S J Drug Target; 2021 Apr; 29(4):349-364. PubMed ID: 33210953 [TBL] [Abstract][Full Text] [Related]
10. Current Strategies of Antiviral Drug Discovery for COVID-19. Mei M; Tan X Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887 [TBL] [Abstract][Full Text] [Related]
11. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205 [TBL] [Abstract][Full Text] [Related]
12. Precision therapeutic targets for COVID-19. Krumm ZA; Lloyd GM; Francis CP; Nasif LH; Mitchell DA; Golde TE; Giasson BI; Xia Y Virol J; 2021 Mar; 18(1):66. PubMed ID: 33781287 [TBL] [Abstract][Full Text] [Related]
13. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection. Khare P; Sahu U; Pandey SC; Samant M Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476 [TBL] [Abstract][Full Text] [Related]
14. An update review of emerging small-molecule therapeutic options for COVID-19. Tian D; Liu Y; Liang C; Xin L; Xie X; Zhang D; Wan M; Li H; Fu X; Liu H; Cao W Biomed Pharmacother; 2021 May; 137():111313. PubMed ID: 33556871 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective. Seifert M; Bera SC; van Nies P; Kirchdoerfer RN; Shannon A; Le TT; Meng X; Xia H; Wood JM; Harris LD; Papini FS; Arnold JJ; Almo S; Grove TL; Shi PY; Xiang Y; Canard B; Depken M; Cameron CE; Dulin D Elife; 2021 Oct; 10():. PubMed ID: 34617885 [TBL] [Abstract][Full Text] [Related]
17. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092 [TBL] [Abstract][Full Text] [Related]
18. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M J A; Francis D; C S S; K G A; C S; Variyar EJ J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185 [TBL] [Abstract][Full Text] [Related]
19. Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2. Tripathi PK; Upadhyay S; Singh M; Raghavendhar S; Bhardwaj M; Sharma P; Patel AK Int J Biol Macromol; 2020 Dec; 164():2622-2631. PubMed ID: 32853604 [TBL] [Abstract][Full Text] [Related]